

(19)



Europäisches Patentamt

European Patent Office

Office européen des brevets



(11)

EP 1 138 766 A2

(12)

## EUROPEAN PATENT APPLICATION

(43) Date of publication:  
04.10.2001 Bulletin 2001/40

(51) Int Cl.7: C12N 15/12, C12P 21/02,  
G01N 33/566

(21) Application number: 01114291.6

(22) Date of filing: 15.10.1993

(84) Designated Contracting States:  
AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL  
PT SE

- Fukuyama, Mayumi  
Kusatsu-shi, Shiga 525 (JP)
- Uchiyama, Takehiko  
Higashimurayama-shi, Tokyo 189 (JP)

(30) Priority: 15.10.1992 JP 27743092  
25.12.1992 JP 34591592  
25.12.1992 JP 34591692  
25.12.1992 JP 34591792  
25.12.1992 JP 34591892

(74) Representative:  
Denison, Christopher Marcus et al  
Mewburn Ellis  
York House  
23 Kingsway  
GB-London WC2B 6HP (GB)

(62) Document number(s) of the earlier application(s) in  
accordance with Art. 76 EPC:  
93922634.6 / 0 636 696

## Remarks:

This application was filed on 13 - 06 - 2001 as a  
divisional application to the application mentioned  
under INID code 62.

(71) Applicant: TORAY INDUSTRIES, INC.  
Tokyo 103 (JP)

(72) Inventors:  
• Miwa, Keishi  
Takatsuki-shi, Osaka 569 (JP)

(54) **Process for preparing major histocompatibility antigen class II protein and materials having the same immobilized thereon**

(57) This invention provides a process for producing major histocompatibility antigen class II protein (herein-after referred to as "MHC class II" for short) which occurs on the surfaces of antigen-presenting cells and the like, and MHC class II-bound materials in which MHC class II,  $\alpha$  and/or  $\beta$  subunit of MHC class II, or a part thereof

is bound to a carrier such as beads, fibers and hollow fibers via covalent bond, as well as a module for removing superantigen using the same.

This invention also provides a method for detecting or quantifying superantigens using MHC class II or a part thereof having an affinity to the superantigens, as well as an assay kit therefor.




Fig. 1 Vector for Expressing  $\alpha$  Subunit of MHC Class II

EP 1 138 766 A2

## Description

### TECHNICAL FIELD

[0001] The present invention relates to a process for producing major histocompatibility antigen class II protein (hereinafter referred to as "MHC class II" for short) occurring on the surface of antigen-presenting cells and the like, and MHC class II-bound materials in which MHC class II,  $\alpha$  and/or  $\beta$  subunit of MHC class II, or a part thereof is bound to a carrier such as beads, fibers and hollow fibers via covalent bond, as well as a module for removing superantigens using the same.

[0002] This invention also relates to a method for detecting or quantifying superantigens using MHC class II or a part thereof having an affinity to superantigens, as well as an assay kit therefor.

### PRIOR ART

[0003] MHC class II occurs on the cell surfaces of B cells, macrophages, endothelium cells in blood vessels and the like. MHC class II is a glycoprotein used for distinguishing self from others. Recently, it was found that MHC class II is a binding protein which binds to a group of proteins called superantigens such as toxins of bacteria, and the subtypes of MHC class II in patients suffering from autoimmune diseases are peculiarly distributed, so that it is now regarded as importance in the field of medicine and immunology.

[0004] Superantigens are a group of proteins which bind to MHC class II on antigen-presenting cells without being processed in the antigen-presenting cells unlike conventional antigens, and form complexes with MHC class II so as to stimulate T cells having a specific V region, thereby abnormally activate immune system.

[0005] Superantigens hitherto confirmed include Staphylococcus aureus toxin, Streptococcus toxin, Yersinia toxin, some kinds of virus proteins and heat shock proteins. Superantigens may also be identified in the future.

[0006] At present, to isolate and obtain MHC class II, it is necessary to introduce MHC class II gene in mammalian cells or insect cells and express the gene, or it is necessary to purify naturally occurring MHC class II from cell membranes of B cells, macrophages, endothelium cells in blood vessels and the like.

[0007] However, for obtaining naturally occurring MHC class II from cell membranes in a large scale, a large number of cells are necessary because the amount of MHC class II on the surface of the membranes is small, so that this method takes a long time and a large cost even if cultured cells are employed.

[0008] Similarly, for producing recombinant MHC class II by mammalian cells or insect cells by a genetic recombination technique, a large cost and a long time are required for culturing the cells.

[0009] Although system for expressing major histocompatibility antigen class I protein by using Es-

cherichia coli has been reported (K.C. Parker et al., Molecular Immunology, Vol. 29, 371 (1992)), no such an expression system is known for MHC class II.

[0010] Conventional materials to which MHC class II is bound include those in which whole cells expressing MHC class II on the cell surfaces are adsorbed on a plate, and those in which chemically synthesized amino acid sequence that is a part of a subunit of MHC class II is adsorbed on a material (J.K. Russel et al., Biochemical and Biophysical Research Communications, Vol. 168, 696 (1990)).

[0011] As for a material for adsorbing superantigens, a material to which antibodies specific to superantigens are immobilized has been reported and the material is used for immunoassays of the superantigens.

[0012] The present invention provides a process for producing MHC class II by using bacteria, thereby promoting productivity and ease of operation.

[0013] Unlike insect cells and mammalian cells, bacterial cells grow fast, no expensive components such as fetal calf serum and growth factors are necessary to be contained in culture medium, and operations such as subculturing and replacement of culture medium are not necessary.

[0014] However, in many cases, proteins originating from mammals are not expressed in bacteria such as E. coli because of the problems such as the toxicity to bacteria and the like.

[0015] The present inventors studied to improve various expression vectors and succeeded in expressing MHC class II in bacterial cells such as E. coli, yeasts and Bacillus subtilis, thereby made it possible to produce the protein efficiently in a large scale.

[0016] The present invention provides, in the medical field, a blood-purification system for removing pathogenic substances including superantigens, which have affinities to MHC class II, and in the field of immunology, the present invention provides a material capable of binding the pathogenic substances including superantigens, which have affinities to MHC class II, that is used for isolating the pathogenic substances and for immunoassays for assaying the pathogenic substances.

[0017] If the whole cells are immobilized on a carrier, since proteins other than MHC class II are also immobilized, the material may have an unknown activity. Further, the freedom of optionally selecting the density of immobilized MHC class II is limited. As for the material on which a chemically synthesized partial amino acid sequence of the MHC class II subunit is adsorbed, although it can be used for detecting superantigens contained in a high concentration in a buffer, it cannot be used for removing superantigens from the blood because the adsorbed ligand may be liberated from the carrier.

[0018] Further, the binding ability of the partial sequence to superantigens is small, so that sufficient performance for detecting and quantifying superantigens cannot be obtained. With the material on which an an-

tibody is immobilized, it is necessary to immobilize different antibodies each of which is specific to each type of superantigens respectively.

#### DISCLOSURE OF THE INVENTION

[0019] The present invention aims at overcoming the above-mentioned problems in the prior art and has the following constitution. That is, the present invention provides

- (1) A process for producing major histocompatibility antigen class II protein, comprising the step of transforming a microorganism with a gene encoding said major histocompatibility antigen class II protein;
- (2) A material in which major histocompatibility antigen class II protein or a part thereof is bound via covalent bond;
- (3) A material in which  $\alpha$  subunit of major histocompatibility antigen class II protein or a part thereof is bound via covalent bond;
- (4) A material in which  $\beta$  subunit of major histocompatibility antigen class II protein or a part thereof is bound via covalent bond;
- (5) A module for removing superantigens, comprising said material of any one of (2) - (4);
- (6) A method for detecting a superantigen by using major histocompatibility antigen class II protein or a part thereof having a length of not less than 40 amino acid residues, which part has an affinity to said superantigen; and
- (7) A method for quantifying a superantigen by using major histocompatibility antigen class II protein or a part thereof having a length of not less than 40 amino acid residues, which part has an affinity to said superantigen.

#### BRIEF DESCRIPTION OF THE DRAWINGS

##### [0020]

Fig. 1 is a schematic view showing an expression vector for expressing MHC class II  $\alpha$  subunit gene in *E. coli*.

Fig. 2 is a schematic view showing an expression vector for expressing MHC class II  $\beta$  subunit gene in *E. coli*.

Fig. 3 shows the relationship between the amount of removed TSST-1 from a buffer solution by MHC class II-bound beads and reaction time.

Fig. 4 shows the relationship between the amount of removed TSST-1 from a buffer solution by MHC class II-bound hollow fibers and reaction time.

Fig. 5 shows the relationship between the SEA level and the absorbance at 450 nm in enzyme immunoassay (sandwich method) employing a plate to which MHC class II,  $\beta$  subunit of MHC class II or a

partial sequence of  $\beta$  subunit of MHC class II is bound.

#### BEST MODE FOR CARRYING OUT THE INVENTION

[0021] The gene encoding MHC class II used in the present invention was obtained by synthesizing DNA primers for PCR based on the reported DNA sequence (L. J. Stern et al., Cell, Vol. 68, p.465, (1992), D. A. Wettstein et al., J. Exp. Med. Vol. 174, p219, (1991)); and amplifying the gene in human cells such as B cells by conventional PCR method described in, for example, "PCR Method for Gene Amplification" (PROTEINS, NUCLEIC ACIDS AND ENZYMES, additional edition, Vol. 35, No. 17 (1990)). The protein encoded by the gene may be obtained by expressing the gene in *E. coli* cells, yeast cells, insect cells or mammalian cells according to a genetic recombination technique.

[0022] Among the cells just mentioned above, in view of the growth rate, production efficiency and ease of operations such as culturing, it is preferred to employ *E. coli* cells, yeast cells and *B. subtilis* cells. The protein may be expressed by ligating the gene with one of various known expression vectors after adding to the gene or a fragment thereto an initiation codon, a termination codon, and if it is desired to secrete the protein outside the cells, a sequence for secretion, and by expressing the gene or the fragment thereof directly. Alternatively, the protein or a fragment thereof may be expressed in the form of a fused protein with another peptide, such as interleukin 2, maltose-binding protein,  $\beta$ -galactosidase, trpE or the like. Further, in view of ease of purification of the protein after expression, hexamer of histidine or the like may be added as long as the activity of MHC class II is retained.

[0023] In view of the toxicity of MHC class II to the bacteria, it is preferred to form inclusion body in the form of a fused protein when the gene is expressed, or to employ a promoter having a high ability to control initiation of transcription, such as T7 ribonuclease promoter or heat shock promoter. It is also possible to introduce a recognition site of a protease (e.g., activated blood coagulation factor X (Factor Xa) and IgA protease) or a cleavage site by a chemical reagent (e.g., cyanogen bromide) between MHC class II and the other protein fused with MHC class II. By so doing, MHC class II may be separated from the other protein after expression of the gene. After expression, MHC class II may be purified by known methods including precipitation by ammonium sulfate, ion-exchange chromatography, affinity chromatography, gel permeation chromatography and hydrophobic chromatography. Further, the method described in METHOD IN ENZYMOLOGY (Academic Press, 1980) may also be applied. The disulfide bond of the subunits may be corrected by adding protein disulfide isomerase, thioredoxin, prothionine, glutathione,  $\beta$ -mercaptoethanol or the like.

[0024] To reconstitute MHC class II after expressing

$\alpha$  subunit and  $\beta$  subunit separately, equimolar of the subunits are mixed and the mixture is left to stand at 4 - 60°C, preferably 20 - 40°C for not less than 5 minutes, preferably not less than 60 minutes.

**[0025]** When mixing the subunits, a small amount of a denaturing agent (e.g., 1 M urea, 10% acetonitrile and the like) may be added, and the reconstitution may be accomplished while dialyzing the mixture within the above-mentioned temperature range.

**[0026]** The material according to the present invention to which MHC class II is bound may be obtained by binding the naturally occurring MHC class II or  $\alpha$  and/or  $\beta$  subunit thereof or a part thereof obtained from cell membranes, or recombinant MHC class II obtained from transformed cells or bacteria, or  $\alpha$  and/or subunit thereof or a part thereof to a carrier such as beads, fibers, hollow fibers, textile, plate or tube via covalent bond.

**[0027]** It is preferred to use a recombinant MHC class II, especially one produced by *E. coli* or a yeast is preferred since large amount of MHC class II can be obtained efficiently.

**[0028]** Thus, the present inventors studied expression and binding of MHC class II, as well as the carrier, to succeed in developing a material to which MHC class II is bound without losing its activity. The details will now be described.

#### (1) MHC class II

**[0029]** As the MHC class II, naturally occurring MHC class II isolated from antigen-presenting cells such as B cells and monocytes with or without stimulating the cells with  $\gamma$ -interferon or the like may be employed.

Alternatively, recombinant MHC class II purified from MHC class II-producing cells obtained by transforming mammalian cells such as CHO cells and L cells or insect cells may be employed. It is preferred to employ a recombinant MHC class II, especially one produced by *E. coli*, a yeast or *B. subtilis*, because a large amount of the protein can be obtained efficiently. Even if a subunit of MHC class II or a part thereof is bound to a carrier, the material has a binding ability. However, in view of the strength of the binding, it is preferred that the part of MHC class II to be bound to the carrier preferably has not less than 40 amino acid residues. More preferably,  $\alpha$ , $\beta$  complex is employed.

#### (2) Method for Immobilization

**[0030]** MHC class II may be immobilized by utilizing covalent bond, ionic bond, coordinate bond or hydrophobic bond, or by inclusion method or by adsorption. To prevent liberation of the immobilized protein, binding the protein via covalent bond is best preferred.

**[0031]** When binding a protein to a carrier, amino group, carboxylic group or sulfide group of the protein is usually utilized. In view of the fact that the binding site to superantigens is located in the N-terminal region of

MHC class II, it is preferred to utilize carboxylic group for binding the protein.

#### (4) Carrier for Immobilizing Protein

**[0032]** As the carrier on which MHC class II is immobilized, beads, fibers, hollow fibers, plates and tubes made of synthetic polymers such as polymethylmethacrylates, polystyrenes, polysulfones, polyallylamines, polyvinylalcohols and derivatives thereof; naturally occurring polymers such as cellulose, chitosan and derivatives thereof; and inorganic materials such as ceramics and metals may be employed. Among these, polymeric compounds in which a functional group can easily be inserted are preferred as the material for binding MHC class II. In view of the ease of operation and large surface area, the carrier is preferably in the form of hollow fibers, beads, fibers and textiles.

**[0033]** By studying the binding method of MHC class II to a carrier, by which the activity of MHC class II can be utilized at maximum, the present inventors succeeded in providing a module for purifying blood by which superantigens are specifically captured.

**[0034]** Further, in a method for detecting or quantifying superantigens, by using MHC class II,  $\alpha$  subunit of MHC class II,  $\beta$  subunit of MHC class II or a part thereof, it was attained for capturing all superantigens by using one material in which the protein or a part thereof is immobilized.

**[0035]** Since the binding ability to superantigens is influenced by three-dimensional structure of the protein, in order to firmly binding superantigens, the part of the protein has amino acid residues of not less than 30, preferably not less than 40. To immobilize the whole subunit is more preferred and binding MHC class II constituted from  $\alpha$  and  $\beta$  subunits are best preferred.

**[0036]** The invention will now be described by way of examples thereof. It should be noted, however, the present invention is not restricted to the examples.

#### EXAMPLES

##### Example 1

##### Expression of MHC class II $\alpha$ Subunit in *E. coli*

**[0037]** The  $\alpha$  subunit of MHC class II was prepared as follows:

**[0038]** Between the *Eco* RI site and *Xba* I site of pUEF having a heat shock promoter, a sequence encoding  $\beta$  galactosidase and a sequence encoding the recognition site of activated blood coagulation factor. Factor Xa, the gene encoding  $\alpha$  subunit of MHC class II was inserted (Fig. 1). *E. coli* was transformed with this vector. After culturing the *E. coli* cells at 30°C for 8 hours, the temperature of the culture medium was raised to 42°C and kept at this temperature for 15 minutes to induce the production of the protein. Thereafter, the temperature of the

culture medium was lowered to 37°C and the cells were cultured at this temperature for 2 hours. The *E. coli* cells were then harvested.

**[0039]** Since MHC class II is produced in the form of a protein fused with  $\beta$  galactosidase, the fused protein can be purified by using a column to which p-aminophenyl-1-thio- $\beta$ -D-galactopyranoside is fixed. Further, since the fused protein has a recognition site of Factor Xa between  $\beta$  galactosidase and MHC class II,  $\alpha$  subunit of MHC class II which does not contain the protective protein  $\beta$  galactosidase can be obtained by digesting the fused protein with Factor Xa after expressing the fused protein.

#### Example 2

##### Expression of $\beta$ Subunit of MHC class II in the Form of Insoluble Protein

**[0040]**  $\beta$  subunit of MHC class II was prepared as follows:

**[0041]** The gene encoding  $\beta$  subunit of MHC class II was inserted between *Eco* RI site and *Hind* III site of pTI vector having tryptophan promoter, a sequence encoding trpE protein and a sequence encoding the recognition site of IgA protease (Fig. 2). *E. coli* was transformed with this vector. After culturing the *E. coli* cells at 37°C for 8 hours in M9 medium, indole acrylic acid was added to induce the production of the protein. The cells were further cultured for 2 hours after the induction and *E. coli* cells were harvested from the culture medium.

**[0042]** Since  $\beta$  subunit of MHC class II is produced in the form of a fused protein with trpE protein, the desired protein is precipitated in the insoluble fraction. After washing the insoluble fraction with Tris buffer containing 2 M urea, the desired fused protein was solubilized by using Tris buffer containing 8 M urea. When the fused protein is solubilized, by adding 1 mM dithiothreitol or 2%  $\beta$  mercaptoethanol as a reducing agent, the recovery of the fused protein is promoted. Immediately after the solubilization, fractionation based on molecular weight is performed by gel permeation chromatography so as to separate the desired fused protein from contaminating lipids and other highly insoluble proteins. Thereafter, the fraction containing the desired fused protein is dialyzed in 20 mM Tris-HCl buffer (pH 7.4) including 50 mM sodium chloride buffer. After the dialysis, no precipitate is formed so that 100% of the fused protein can be recovered. Although the desired protein is obtained in the soluble fraction without the above-mentioned fractionation according to molecular weight, most part of the obtained protein is precipitated in the insoluble fraction after dialysis.

**[0043]**  $\beta$  subunit of MHC class II which does not contain trpE protein that is a protective protein can be obtained by digesting the obtained soluble fraction with IgA protease, and by purifying the  $\beta$  subunit by hydrophobic chromatography, ion-exchange chromatography, gel

permeation chromatography or the like. The purification by hydrophobic chromatography or ion-exchange chromatography may be performed before the digestion by the protease.

#### Example 3

##### Reconstruction of MHC class II from $\alpha$ and $\beta$ Subunits

**[0044]** The  $\alpha$  subunit and the  $\beta$  subunit of MHC class II prepared in Examples 1 and 2, respectively, are dissolved in Tris-HCl buffer (pH 7.4) containing 8 M urea, 10 mM magnesium chloride and 100 mM sodium chloride, to a concentration of 5 mg/ml each. Thereafter, the resulting solution is dialyzed in 10 mM magnesium chloride solution containing 1 M urea and in Tris-HCl buffer (pH 7.4) containing 100 mM sodium chloride at 4°C. After the dialysis, the resultant is further dialyzed in 10 mM magnesium chloride solution containing no urea and in Tris-HCl buffer (pH 7.4) containing 100 mM sodium chloride. By these operations, MHC class II complex can be obtained.

#### Example 4

**[0045]** MHC class II produced by *E. coli* was bound to beads. This was accomplished as follows: MHC class II was dissolved in 5 ml of 50 mM borate buffer (pH 8.0) to a concentration of 1 mg/ml. To this aqueous solution, 1 ml of chitosan beads having succinimide groups were added and the resulting mixture was allowed to react at 4°C for 8 hours. After the reaction, inactivation of the non-reacted functional groups and washing of non-reacted protein were performed with 50 ml of 0.5 M Tris-HCl buffer (pH 8.0). Amino acid analysis of the obtained beads revealed that the amount of the protein bound to the beads was 2.3 mg per 1 ml of beads. In an aqueous solution containing exotoxin of *Staphylococcus aureus* (TSST-1) in a concentration of 1 ng/ml, 0.5 ml of the thus obtained MHC class II-bound beads were added. For comparison, 0.5 ml of chitosan beads having succinimide groups, which were reacted only with Tris-HCl buffer were also separately added to the TSST-1 solution. As shown in Fig. 3, adsorption of the toxin was observed only in the solution to which MHC class II-bound beads were added. Thus, it was confirmed that MHC class II was bound to the beads via covalent bond while retaining the binding ability to the toxin. In Fig. 3,  $\circ$  indicates the results of the test using MHC class II-bound beads and  $\bullet$  indicates the results of the test using non-reacted beads. Only with MHC class II-bound beads, the reduction of TSST-1 concentration was observed.

#### Example 5

**[0046]** MHC class II produced by *E. coli* was bound to hollow fiber membranes as follows: MHC class II was dissolved in 5 ml of 50 mM borate buffer (pH 8.0) to a

concentration of 1 mg/ml. To the obtained aqueous solution, 1 g of polysulfone hollow fibers having amino groups were added and the mixture was allowed to react at 4°C for 8 hours.

[0047] To the reaction mixture, carbodiimide was added as a catalyst. Amino acid analysis of the obtained hollow fibers revealed that 2.0 mg of protein was bound per 1 g of the hollow fibers. A module was prepared using 0.5 g of the thus obtained MHC class II-bound hollow fibers. For comparison, a module was also prepared using 0.5 g of hollow fibers which were not reacted with MHC class II. A serum containing exotoxin of *Staphylococcus aureus* (TSST-1) in a concentration of 1 ng/ml was circulated in each module. As a result, as shown in Fig. 4, adsorption of the toxin was observed only with MHC class II-bound hollow fibers. Thus, it was proved that removal of the toxin from blood can be attained by MHC class II-bound hollow fibers. In Fig. 4, ○ indicates the results of the test using MHC class II-bound hollow fibers and • indicates the results of the test using non-reacted hollow fibers. Only with MHC class II-bound hollow fibers, the reduction of TSST-1 concentration was observed.

#### Example 6

[0048] MHC class II extracted from B cells, β subunit of MHC class II produced by *E. coli*, or a partial amino acid sequence of β subunit of MHC class II (30 amino acid residues which is said to have binding ability to superantigens) was dissolved in PBS to a concentration of 10 μg/ml. Each of the solutions was placed in an amount of 0.1 ml in the wells of a 96-well microplate having amino groups, and carbodiimide as a catalyst was added thereto. Each of the mixtures was left to stand overnight at 4°C to immobilize the protein. After blocking the wells with PBS solution containing 0.5% bovine serum albumin (BSA), the wells were washed with a washing solution (PBS containing 0.05% Tween 20).

[0049] With the thus prepared MHC class II-bound plate, SEA which is exotoxin of *Staphylococcus aureus* and is a superantigen was reacted. As a control, SEA was reacted with a plate to which BSA alone was immobilized. Thereafter, anti-SEA monoclonal antibody (labelled with biotin), avidin-conjugated peroxidase, and 3,3',5,5'-tetramethylbenzidine were sequentially reacted, and the generated color was measured. The results are shown in Fig. 5. Coloring was scarcely observed in the plate to which BSA alone was immobilized. Coloring was observed in the plates to which MHC class II (about 400 amino acid residues), β subunit (about 200 amino acid residues), or the peptide having a partial amino acid sequence (50 amino acid residues or 30 amino acid residues) was bound, so that binding of SEA was confirmed. ○ indicates the results obtained with the MHC class II-bound plate, Δ indicates the results obtained with the β subunit-bound plate, • indicates the results obtained with the partial amino acid sequence of β sub-

unit-bound plate (50 amino acid residues), ▲ indicates the results obtained with the partial amino acid sequence of β subunit-bound plate (30 amino acid residues), and ■ indicates the results obtained in the control (BSA-immobilized plate).

[0050] With the increase in the number of amino acid residues, detection sensitivity is increased, and with an sequence having not less than 50 amino acid residues, SEA at a concentration of 1 μg/ml can be detected. With the MHC class II-bound plate and the β subunit of MHC class II-bound plate, the relationship between the coloring and SEA level is linear within the range of the SEA level from 0 to 1 μg/ml and from 10<sup>3</sup> to 10<sup>6</sup> ng/ml, respectively. Thus, it was proved that quantification of SEA can be attained.

#### INDUSTRIAL AVAILABILITY

[0051] By the present invention, major histocompatibility antigen class II protein which is hitherto produced by using mammalian cells or insect cells can be produced efficiently at a low cost in a large scale by using bacterial cells.

[0052] The present invention also provides a material which is useful for adsorbing, separating, detecting or quantifying superantigens or the like, such as exotoxin of *Staphylococcus aureus* in aqueous solutions, body fluids such as blood and urine, foods and drinks. Thus, the present invention may be effectively employed in studies in medicine, immunology and biochemistry as well as in clinical applications, for example, for constructing therapeutic systems for sepsis and autoimmune diseases.


#### Claims

1. A material in which major histocompatibility antigen class II protein or a part thereof is bound via covalent bond.
2. A material in which α subunit of major histocompatibility antigen class II protein or a part thereof is bound via covalent bond.
3. A material in which β subunit of major histocompatibility antigen class II protein or a part thereof is bound via covalent bond.
4. The material according to any one of claims 1 - 3, wherein hollow fiber membranes, fibers, beads or textiles are used as carriers for binding the protein.
5. A module for removing superantigens, comprising said material according to any one of claims 1 - 3.
6. The module according to claim 5, which is a module for purifying blood.

7. A method for detecting a superantigen by using major histocompatibility antigen class II protein or a part thereof having a length of not less than 40 amino acid residues, which part has an affinity to said superantigen. 5
8. A method for detecting a superantigen by using  $\alpha$  subunit of major histocompatibility antigen class II protein or a part thereof having a length of not less than 40 amino acid residues, which part has an affinity to said superantigen. 10
9. A method for detecting a superantigen by using  $\beta$  subunit of major histocompatibility antigen class II protein or a part thereof having a length of not less than 40 amino acid residues, which part has an affinity to said superantigen. 15
10. A method for quantifying a superantigen by using major histocompatibility antigen class II protein or a part thereof having a length of not less than 40 amino acid residues, which part has an affinity to said superantigen. 20
11. A method for quantifying a superantigen by using  $\alpha$  subunit of major histocompatibility antigen class II protein or a part thereof having a length of not less than 40 amino acid residues, which part has an affinity to said superantigen. 25
12. A method for detecting a superantigen by using  $\beta$  subunit of major histocompatibility antigen class II protein or a part thereof having a length of not less than 40 amino acid residues, which part has an affinity to said superantigen. 30
13. A kit for detecting and/or quantifying the superantigen in accordance with the method claimed in any one of claims 7 - 12. 35
14. A process for producing major histocompatibility antigen class II protein, comprising the step of transforming a microorganism with a gene encoding said major histocompatibility antigen class II protein. 40
15. The process for producing major histocompatibility antigen class II protein according to claim 1, wherein said microorganism is selected from the group consisting of Escherichia coli, yeasts and Bacillus subtilis. 45
16. The process for producing major histocompatibility antigen class II protein according to claim 1, wherein said gene encoding said major histocompatibility antigen class II protein is expressed in a host cell so that an insoluble protein is produced, and said insoluble protein is then modified to a soluble pro- 50


tein.

17. The process for producing major histocompatibility antigen class II protein according to claim 1, wherein  $\alpha$  subunit and  $\beta$  subunit of said major histocompatibility antigen class II protein are separately produced and said protein is then reconstituted from said subunits



Prh : heat shock promoter  
 bla :  $\beta$  lactamase gene  
 lacZ :  $\beta$  galactosidase gene  
 MHC  $\alpha$  : MHC class II  $\alpha$  subunit gene  
 FactorXa site : recognition site of protease Factor Xa

Fig. 1 Vector for Expressing  $\alpha$  Subunit of MHC Class II



Prt : tryptophan promoter  
 bla :  $\beta$  lactamase gene  
 trpE : TrpE protein gene  
 MHC  $\beta$  : MHC class II  $\beta$  subunit gene  
 IgAprotease site : recognition site of IgA protease

Fig. 2 Vector for Expressing  $\beta$  Subunit of MHC Class II






Fig. 3




Fig. 4





Fig. 5



(12) EUROPEAN PATENT APPLICATION

(88) Date of publication A3:  
02.05.2003 Bulletin 2003/18

(51) Int Cl.7: C12N 15/12, C12P 21/02,  
G01N 33/566

(43) Date of publication A2:  
04.10.2001 Bulletin 2001/40

(21) Application number: 01114291.6

(22) Date of filing: 15.10.1993

(84) Designated Contracting States:  
AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL  
PT SE

(30) Priority: 15.10.1992 JP 27743092  
25.12.1992 JP 34591592  
25.12.1992 JP 34591692  
25.12.1992 JP 34591792  
25.12.1992 JP 34591892

(62) Document number(s) of the earlier application(s) in  
accordance with Art. 76 EPC:  
93922634.6 / 0 636 696

(71) Applicant: TORAY INDUSTRIES, INC.  
Tokyo 103 (JP)

(72) Inventors:  
• Miwa, Keishi  
Takatsuki-shi, Osaka 569 (JP)  
• Fukuyama, Mayumi  
Kusatsu-shi, Shiga 525 (JP)  
• Uchiyama, Takehiko  
Higashimurayama-shi, Tokyo 189 (JP)


(74) Representative:  
Denison, Christopher Marcus et al  
Mewburn Ellis  
York House  
23 Kingsway  
London WC2B 6HP (GB)

(54) Process for preparing major histocompatibility antigen class II protein and materials having the same immobilized thereon

(57) This invention provides a process for producing major histocompatibility antigen class II protein (hereinafter referred to as "MHC class II" for short) which occurs on the surfaces of antigen-presenting cells and the like, and MHC class II-bound materials in which MHC class II,  $\alpha$  and/or  $\beta$  subunit of MHC class II, or a part thereof

is bound to a carrier such as beads, fibers and hollow fibers via covalent bond, as well as a module for removing superantigen using the same.

This invention also provides a method for detecting or quantifying superantigens using MHC class II or a part thereof having an affinity to the superantigens, as well as an assay kit therefor.



Prh : heat shock promoter  
bla :  $\beta$  lactamase gene  
lacZ :  $\beta$  galactosidase gene  
MHC  $\alpha$  : MHC class II  $\alpha$  subunit gene  
FactorXa site : recognition site of protease Factor Xa

Fig. 1 Vector for Expressing  $\alpha$  Subunit of MHC Class II



European Patent  
Office

# EUROPEAN SEARCH REPORT

Application Number  
EP 01 11 4291

DOCUMENTS CONSIDERED TO BE RELEVANT			
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	CLASSIFICATION OF THE APPLICATION (Int.Cl.7)
X	WO 89 12459 A (BIOSPAN CORP) 28 December 1989 (1989-12-28) * page 20, line 30 - page 21, line 26 * * page 23, line 21 - line 25 *	1-3	C12N15/12 C12P21/02 G01N33/566
Y	* page 25, line 1 - line 26; figure 1 * ---	1-6	
X	EP 0 432 691 A (YEDA RES & DEV) 19 June 1991 (1991-06-19)	1-4	
Y	* page 3, line 32 - page 4, line 25; claims *	7-13	
Y	WO 91 14701 A (UNIV LELAND STANFORD JUNIOR) 3 October 1991 (1991-10-03) * page 5 - page 15 * * page 28 *	7-13	
Y	KANE K P ET AL: "SOLID-PHASE BINDING OF CLASS I AND II MHC PROTEINS IMMUNOASSAY AND T CELL RECOGNITION" MOLECULAR IMMUNOLOGY, vol. 26, no. 8, 1988, pages 759-768, XP001105788 ISSN: 0161-5890 * discussion * * page 762, left-hand column *	1-6	TECHNICAL FIELDS SEARCHED (Int.Cl.7)  C07K G01N
Y	RUSSELL J K ET AL: "THE I-A-BETA-B REGION 65-85 IS A BINDING SITE FOR THE SUPERANTIGEN STAPHYLOCOCCAL ENTEROTOXIN A" BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, vol. 168, no. 2, 1990, pages 696-701, XP001105423 ISSN: 0006-291X * the whole document *	7-13	
-/--			
-The present search report has been drawn up for all claims			
Place of search <b>MUNICH</b>		Date of completion of the search <b>20 September 2002</b>	Examiner <b>Kania, T</b>
<p>CATEGORY OF CITED DOCUMENTS</p> <p>X : particularly relevant if taken alone Y : particularly relevant if combined with another document of the same category A : technological background O : non-written disclosure P : intermediate document</p> <p>T : theory or principle underlying the invention E : earlier patent document, but published on, or after the filing date D : document cited in the application L : document cited for other reasons &amp; : member of the same patent family, corresponding document</p>			

EPO FORM 1503 03.82 (P04C 01)



European Patent  
Office

Application Number  
EP 01 11 4291

**CLAIMS INCURRING FEES**

The present European patent application comprised at the time of filing more than ten claims.

- ☐ Only part of the claims have been paid within the prescribed time limit. The present European search report has been drawn up for the first ten claims and for those claims for which claims fees have been paid, namely claim(s):
- ☐ No claims fees have been paid within the prescribed time limit. The present European search report has been drawn up for the first ten claims.

**LACK OF UNITY OF INVENTION**

The Search Division considers that the present European patent application does not comply with the requirements of unity of invention and relates to several inventions or groups of inventions, namely:

see sheet 8

- ☐ All further search fees have been paid within the fixed time limit. The present European search report has been drawn up for all claims.
- ☐ As all searchable claims could be searched without effort justifying an additional fee, the Search Division did not invite payment of any additional fee.
- ☐ Only part of the further search fees have been paid within the fixed time limit. The present European search report has been drawn up for those parts of the European patent application which relate to the inventions in respect of which search fees have been paid, namely claims:
- ☒ None of the further search fees have been paid within the fixed time limit. The present European search report has been drawn up for those parts of the European patent application which relate to the invention first mentioned in the claims, namely claims:

1-13



European Patent  
Office

# EUROPEAN SEARCH REPORT

Application Number  
EP 01 11 4291

DOCUMENTS CONSIDERED TO BE RELEVANT			
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	CLASSIFICATION OF THE APPLICATION (Int.Cl.7)
A	MOLLICK J A ET AL: "CLASS II MHC MOLECULES ARE SPECIFIC RECEPTORS FOR STAPHYLOCOCCUS ENTEROTOXIN A" SCIENCE (WASHINGTON D C), vol. 244, no. 4906, 1989, pages 817-820, XP001093700 ISSN: 0036-8075 * the whole document *	5,6	
A	EL HABIB R ET AL: "NEW METHOD FOR THE SPECIFIC CLEARANCE OF ANTIBODIES USING ANTIGENS LINKED TO A COLLAGEN FILM" BIOMEDICINE & PHARMACOTHERAPY, vol. 36, no. 6-7, 1982, pages 302-307, XP001105713 ISSN: 0753-3322 * the whole document *		
			TECHNICAL FIELDS SEARCHED (Int.Cl.7)
<del>The present search report has been drawn up for all claims</del>			
Place of search MUNICH		Date of completion of the search 20 September 2002	Examiner Kania, T
CATEGORY OF CITED DOCUMENTS X : particularly relevant if taken alone Y : particularly relevant if combined with another document of the same category A : technological background O : non-written disclosure P : intermediate document		T : theory or principle underlying the invention E : earlier patent document, but published on, or after the filing date D : document cited in the application L : document cited for other reasons & : member of the same patent family, corresponding document	

EPO FORM 1503 (3.82 (PC/C))



European Patent  
Office

**LACK OF UNITY OF INVENTION  
SHEET B**

Application Number  
**EP 01 11 4291**

The Search Division considers that the present European patent application does not comply with the requirements of unity of invention and relates to several inventions or groups of inventions, namely:

**1. Claims: 1-13 completely**

A material in which MHC antigen class II or a part thereof is covalently bound, and related subject-matter.  
Methods for detection and quantification of a superantigen by using MHC antigen class II or parts thereof, and related subject-matter.

**2. Claims: 14-17 completely**

A process for producing MHC antigen class II by transforming a microorganism with a gene encoding said MHC antigen class II protein, and related subject-matter.



**ANNEX TO THE EUROPEAN SEARCH REPORT  
ON EUROPEAN PATENT APPLICATION NO.**

EP 01 11 4291

This annex lists the patent family members relating to the patent documents cited in the above-mentioned European search report. The members are as contained in the European Patent Office EDP file on  
The European Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

20-09-2002

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 8912459 A	28-12-1989	US 5194425 A	16-03-1993
		AT 139122 T	15-06-1996
		AU 3963889 A	12-01-1990
		CA 1340327 A1	19-01-1999
		DE 68926675 D1	18-07-1996
		DE 68926675 T2	09-01-1997
		EP 0423201 A1	24-04-1991
		EP 0742014 A1	13-11-1996
		JP 2755458 B2	20-05-1998
		JP 3505731 T	12-12-1991
		KR 9302835 B1	10-04-1993
		WO 8912459 A1	28-12-1989
		US 6106840 A	22-08-2000
		US 5130297 A	14-07-1992
		US 6451314 B1	17-09-2002
		US 5284935 A	08-02-1994
		US 5260422 A	09-11-1993
		US 5468481 A	21-11-1995
EP 0432691 A	19-06-1991	EP 0432691 A1	19-06-1991
		US 6066621 A	23-05-2000
		US 5356779 A	18-10-1994
WO 9114701 A	03-10-1991	US 5364762 A	15-11-1994
		AU 7653991 A	21-10-1991
		EP 0522073 A1	13-01-1993
		WO 9114701 A1	03-10-1991